Aptose Biosciences (NASDAQ:APTO) and Neurocrine Biosciences (NASDAQ:NBIX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.
This is a breakdown of current ratings and price targets for Aptose Biosciences and Neurocrine Biosciences, as reported by MarketBeat.com.
Aptose Biosciences currently has a consensus target price of $6.40, indicating a potential upside of 235.08%. Neurocrine Biosciences has a consensus target price of $102.28, indicating a potential upside of 21.20%. Given Aptose Biosciences’ stronger consensus rating and higher possible upside, analysts clearly believe Aptose Biosciences is more favorable than Neurocrine Biosciences.
Valuation and Earnings
This table compares Aptose Biosciences and Neurocrine Biosciences’ top-line revenue, earnings per share (EPS) and valuation.
Aptose Biosciences has higher earnings, but lower revenue than Neurocrine Biosciences. Aptose Biosciences is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
3.3% of Aptose Biosciences shares are held by institutional investors. Comparatively, 97.8% of Neurocrine Biosciences shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
Aptose Biosciences has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500.
This table compares Aptose Biosciences and Neurocrine Biosciences’ net margins, return on equity and return on assets.
Neurocrine Biosciences beats Aptose Biosciences on 10 of the 13 factors compared between the two stocks.
Aptose Biosciences Company Profile
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-74788, which is in Phase II clinical trial that is used for the treatment of congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, dystonia, and other indications. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. The company also has a research collaboration agreement with Jnana Therapeutics Inc. to discover novel small molecule therapeutics for multiple targets for central nervous system disorders. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.